Skip to main content
Marco Ruella, MD, Hematology, Philadelphia, PA

Marco Ruella MD

Hematologic Oncology


Assistant Professor of Medicine and Scientific Director, Lymphoma Program

Join to View Full Profile
  • 3400 Civic Center BlvdPerelman Center for Advanced Medicine, SPE 8-112Philadelphia, PA 19104

  • Phone+1 215-746-4880

Dr. Ruella is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Penn Medicine
    Penn MedicinePost-Doctoral Fellowship, 2012 - 2018
  • University of Torino
    University of TorinoSpecialty in Hematology, Clinical Hematology and Cell Therapy, cum Laude, 2008 - 2012
  • University of Torino Faculty of Medicine
    University of Torino Faculty of MedicineClass of 2007

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2018 - 2026

Publications & Presentations

PubMed

Journal Articles

  • Induction of Resistance to Chimeric Antigen Receptor T Cell Therapy by Transduction of a Single Leukemic B Cell  
    Vijay G Bhoj, David M Barrett, Carl H June, Stephan A Grupp, David E Ambrose, Saar I Gill, Marco Ruella, Bruce L Levine, Shannon L Maude, Nature
  • Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer  
    Nathan Singh, Marco Ruella, Carl H June, Current Hematologic Malignancy Reports

Abstracts/Posters

  • Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience
    Marco Ruella, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas
    Marco Ruella, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy
    Marco Ruella, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Authored Content

  • The Quest To Cure CLL: “Remarkable” Results With New StrategySeptember 2023
  • Interleukin-18 Secreting Autologous Anti-CD19 CAR T-cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-cell TherapyDecember 2022

Press Mentions

  • Simple Dietary Supplement Could Supercharge Cancer-Fighting Immune Cells
    Simple Dietary Supplement Could Supercharge Cancer-Fighting Immune CellsDecember 29th, 2024
  • Keto Diet Metabolite May Power up CAR T Cells to Kill Cancer
    Keto Diet Metabolite May Power up CAR T Cells to Kill CancerDecember 9th, 2024
  • Keto Diet Might Increase Effectiveness of Certain Cancer Treatment
    Keto Diet Might Increase Effectiveness of Certain Cancer TreatmentDecember 9th, 2024
  • Join now to see all

Grant Support

  • MODULATION OF CD5 SIGNALING TO ENHANCE ADOPTIVE T-CELL THERAPIES FOR CANCERUNIVERSITY OF PENNSYLVANIA2022–2027

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: